These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 24058300

  • 1. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR.
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [Abstract] [Full Text] [Related]

  • 2. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
    Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, Safren S, Tumwesigye E, Celum CL, Bangsberg DR.
    J Acquir Immune Defic Syndr; 2012 Apr 15; 59(5):463-8. PubMed ID: 22267018
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
    Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Panteleeff D, Krows M, Shah H, Revall J, Morrison S, Ondrejcek L, Ingram C, Coombs RW, Lingappa JR, Celum C, Partners PrEP Study Team.
    PLoS One; 2011 Apr 15; 6(10):e25828. PubMed ID: 21998703
    [Abstract] [Full Text] [Related]

  • 4. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2011 Apr 15; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 5. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
    Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, Baeten JM, Partners PrEP Study Team.
    J Acquir Immune Defic Syndr; 2014 Sep 01; 67(1):91-7. PubMed ID: 25118795
    [Abstract] [Full Text] [Related]

  • 6. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, Bangsberg DR, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Kamali A, Priddy FH.
    PLoS One; 2013 Sep 01; 8(9):e74314. PubMed ID: 24086333
    [Abstract] [Full Text] [Related]

  • 7. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team.
    Lancet Infect Dis; 2014 Nov 01; 14(11):1055-1064. PubMed ID: 25300863
    [Abstract] [Full Text] [Related]

  • 8. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
    Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C.
    J Acquir Immune Defic Syndr; 2014 Jul 01; 66(3):340-8. PubMed ID: 24784763
    [Abstract] [Full Text] [Related]

  • 9. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Manongi R, Kapiga S, Kashuba A, Van Damme L, FEM-PrEP Study Group.
    J Acquir Immune Defic Syndr; 2014 Jul 01; 66(3):324-31. PubMed ID: 25157647
    [Abstract] [Full Text] [Related]

  • 10. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 11. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners PrEP Study Team.
    N Engl J Med; 2012 Aug 02; 367(5):399-410. PubMed ID: 22784037
    [Abstract] [Full Text] [Related]

  • 12. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb 02; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 13. An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda.
    Psaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, Wangisi J, Mugwanya K, Kintu A, Enyakoit M, Thomas KK, Donnell D, Krows M, Kidoguchi L, Ware N, Baeten JM, Celum C, Bangsberg DR, Safren SA.
    J Acquir Immune Defic Syndr; 2014 Aug 15; 66(5):522-9. PubMed ID: 24853311
    [Abstract] [Full Text] [Related]

  • 14. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI, Uthman OA, Okoromah CA.
    Cochrane Database Syst Rev; 2012 Jul 11; 2012(7):CD007189. PubMed ID: 22786505
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
    Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM, Partners PrEP Study Team.
    AIDS; 2013 Aug 24; 27(13):2155-60. PubMed ID: 24384592
    [Abstract] [Full Text] [Related]

  • 16. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Priddy FH.
    PLoS One; 2012 Aug 24; 7(4):e33103. PubMed ID: 22511916
    [Abstract] [Full Text] [Related]

  • 17. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J, Dufrene SL, Okulicz JF.
    Ann Pharmacother; 2014 Apr 24; 48(4):507-18. PubMed ID: 24473492
    [Abstract] [Full Text] [Related]

  • 18. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E, Cohan D.
    AIDS; 2013 Jan 02; 27(1):F1-5. PubMed ID: 22914582
    [Abstract] [Full Text] [Related]

  • 19. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
    Krakower D, Mayer KH.
    Ann Intern Med; 2012 Oct 02; 157(7):490-7. PubMed ID: 22821365
    [Abstract] [Full Text] [Related]

  • 20. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
    Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, Asiimwe S, Thomas KK, Celum C, Baeten JM.
    J Int AIDS Soc; 2017 Jul 25; 20(1):21842. PubMed ID: 28741331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.